肥胖和2型糖尿病患者中代谢功能障碍相关脂肪性肝病（MASLD）的患病率：一项横断面研究。
Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Persons with Obesity and Type 2 Diabetes Mellitus: A Cross-sectional Study.
作者信息
Latif Saba, Ahsan Tasnim
机构信息
Department of Endocrinology, Medicell Institute of Diabetes Endocrinology and Metabolism (MIDEM), Karachi, Sindh, Pakistan.
出版信息
Euroasian J Hepatogastroenterol. 2024 Jul-Dec;14(2):129-133. doi: 10.5005/jp-journals-10018-1437. Epub 2024 Dec 27.
BACKGROUND
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important entity in patients with type-2 diabetes (T2D). Exploring the prevalence and related factors of MASLD is vital toward developing effective methods of diagnosis and treatment. The objective of this study was to determine the prevalence of MASLD in persons with obesity and T2D.
MATERIALS AND METHODS
This cross-sectional study was conducted at a private healthcare facility (Medicell Clinics) in Karachi, Pakistan, reviewing records from January to December 2022. Persons of either gender aged 18 or above with a diagnosis of T2D and/or obesity were analyzed.
RESULTS
Of a total of 646 persons, 430 (66.6%) were females. The mean age was 48.58 ± 13.88 years, ranging between 18 and 85 years. T2D was noted in 351 (54.3%) patients, while obesity was observed in 593 (91.8%) persons, 396 (61.3%) had MASLD. Persons having MASLD had significantly higher body mass index (31.16 ± 5.13 vs 28.14 ± 4.76 kg/m, < 0.001). Likewise, obesity was significantly associated with MASLD (94.9 vs 86.8%, < 0.001). The odds ratios (OR) and 95% confidence intervals (CIs) are reported in multivariate logistic regression table. Persons with T2DM (OR = 1.519, = 0.009), and obesity (OR = 2.651, = 0.001) showed significantly increased odds of having MASLD. The analysis revealed that individuals in the age-group of 18-40 (OR = 1.627, = 0.014) had increased odds of having MASLD.
CONCLUSION
The prevalence of MASLD was very high in persons with T2D, and obesity. Type-2 diabetes with or without obesity, or the other way around, significantly increases the risk of MASLD. Therefore, these persons should be screened for MASLD to improve clinical outcomes in the affected people.
HOW TO CITE THIS ARTICLE
Latif S, Ahsan T. Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Persons with Obesity and Type 2 Diabetes Mellitus: A Cross-sectional Study. Euroasian J Hepato-Gastroenterol 2024;14(2):129-133.
背景
代谢功能障碍相关脂肪性肝病（MASLD）是2型糖尿病（T2D）患者中的一个重要病症。探索MASLD的患病率及相关因素对于开发有效的诊断和治疗方法至关重要。本研究的目的是确定肥胖和T2D患者中MASLD的患病率。
材料与方法
这项横断面研究在巴基斯坦卡拉奇的一家私立医疗机构（Medicell诊所）进行，回顾了2022年1月至12月的记录。对年龄在18岁及以上、诊断为T2D和/或肥胖的男女患者进行了分析。
结果
在总共646人中，430人（66.6%）为女性。平均年龄为48.58±13.88岁，范围在18岁至85岁之间。351名（54.3%）患者患有T2D，593名（91.8%）人存在肥胖，396名（61.3%）患有MASLD。患有MASLD的人身体质量指数显著更高（31.16±5.13 vs 28.14±4.76 kg/m²，P<0.001）。同样，肥胖与MASLD显著相关（94.9%对86.8%，P<0.001）。多因素逻辑回归表中报告了优势比（OR）和95%置信区间（CI）。患有T2DM的人（OR = 1.519，P = 0.009）和肥胖者（OR = 2.651，P = 0.001）患MASLD的几率显著增加。分析显示，18 - 40岁年龄组的个体患MASLD的几率增加（OR = 1.627，P = 0.014）。
结论
T2D和肥胖患者中MASLD的患病率非常高。无论有无肥胖的2型糖尿病，或反之，都会显著增加MASLD的风险。因此，应对这些人进行MASLD筛查，以改善受影响人群的临床结局。
如何引用本文
Latif S, Ahsan T. 肥胖和2型糖尿病患者中代谢功能障碍相关脂肪性肝病（MASLD）的患病率：一项横断面研究。欧亚肝脏胃肠病学杂志2024；14(2):129 - 133。
Zotero 插件